My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.
Principal Investigator
Grilley-Olson, Juneko
Protocol No.
ML28897PRO/02
Disease Sites
Bones and Joints
Brain and Nervous System
Breast
Breast - Male
Cervix Uteri
Colon
Corpus Uteri
Esophagus
Eye and Orbit
Kidney
Larynx
Lip, Oral Cavity and Pharynx
Liver
Lung
Melanoma, Skin
Ovary
Pancreas
Prostate
Rectum
Small Intestine
Soft Tissue
Stomach
Thyroid
Urinary Bladder
Drugs Involved
Atezolizumab
HERCEPTIN (TRASTUZUMAB)
PERTUZUMAB
TRASTUZUMAB
alectinib
Phase
Phase II
Contact Info
Email for more information
Or Call 877-668-0683
Participating Sites
UNC-CH
ClinicialTrials.gov
Visit ClinicalTrials.gov for full clinical trial description